Record Details

Maintenance therapy in multiple myeloma

Hematology Reports

View Archive Info
Field Value
Authentication Code dc
Title Statement Maintenance therapy in multiple myeloma
Added Entry - Uncontrolled Name Jean-Luc Harousseau; Rene Gauducheau Cancer Center, Nantes/St Herblain
Uncontrolled Index Term Medicine; Hematology; Haematology; Multiple myeloma;
Medicine; Hematology; Haematology; Multiple myeloma;
Summary, etc. The treatment of multiple myeloma (MM) has changed dramatically in the past twenty years with the introduction of high-dose therapy plus autologous stem-cell transplantation (ASCT) in younger patients and, more recently, of three novel agents (thalidomide, bortezomib, and lenalidomide). When conventional chemotherapy was the only available possibility, complete responses (CR) were very rare and the objective of maintenance was to prolong remission duration by continuing the same type of treatment that induced the initial response. With recent therapeutic improvements, CR achievement becomes a realistic goal that, in most cases, is significantly correlated with the outcome (1). Therefore, both the nature and the impact of maintenance therapy have changed. Maintenance therapy is based currently on novel agents, and its objective is not only to control the clone but also to further decrease the tumor burden and improve the quality of response. A number of randomized studies show a benefit from maintenance therapy with novel agents (until now, mostly thalidomide), at least in terms of response rate and progression-free survival (PFS). However, there is still a debate as concerns the impact on overall survival (OS) and the optimal administration of maintenance therapy.
Publication, Distribution, Etc. PAGEPress Publications
Electronic Location and Access application/pdf
Data Source Entry Hematology Reports; Vol 1, No 2 (2009); e12
Language Note en
Terms Governing Use and Reproduction Note <p>PAGEPress has chosen to apply the <a href="" target="_blank">Creative Commons Attribution License</a> (CCAL) to all manuscripts to be published. </p> <p>An Open Access Publication is one that meets the following two conditions:</p> <ol><li>The author(s) and copyright holder(s) grant(s) to all users a free, irrevocable, worldwide, perpetual right of access to, and a license to copy, use, distribute, transmit and display the work publicly and to make and distribute derivative works, in any digital medium for any responsible purpose, subject to proper attribution of authorship, as well as the right to make small numbers of printed copies for their personal use.</li><li>A complete version of the work and all supplemental materials, including a copy of the permission as stated above, in a suitable standard electronic format is deposited immediately upon initial publication in at least one online repository that is supported by an academic institution, scholarly society, government agency, or other well-established organization that seeks to enable open access, unrestricted distribution, interoperability, and long-term archiving.</li></ol> Authors who publish with this journal agree to the following terms: 1. Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal. 2. Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal. 3. Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).